Compounding Pharmacies.
Scale GLP-1, peptide, HRT, dermatology, sterile and non-sterile lines through prescriber partnerships across multi-state footprints.
PHARMA PARTNERSHIPS
For compounding pharmacies, telehealth organizations, and distributors ready to land clinic, GPO, and international contracts. We find the decision-makers who are evaluating partners right now, and put booked meetings on your calendar.
Buyers are deciding this week. The only question is whose calendar they land on.
WHO THIS IS FOR
Compounding Pharmacies.
Scale GLP-1, peptide, HRT, dermatology, sterile and non-sterile lines through prescriber partnerships across multi-state footprints.
Telehealth Organizations.
Reach medical directors and ops leaders mid-evaluation, and keep them engaged so the cycle doesn't die between calls.
Distributors / Wholesalers.
Land hospital and GPO contracts; open international channels with importers actively seeking US suppliers.
Three buyer types, one common thread: the deal goes to whoever shows up during evaluation.
HOW IT WORKS
Our proprietary pixel and data layer resolve real-time intent and identity — surfacing buyers actively researching things like "telehealth pharmacy partnerships," "GPO contracts," or "US pharmaceutical exporter" while their intent is fresh. You spend against live intent, not stale lists.
Coordinated email, LinkedIn, and targeted ads put you in front of the buyer everywhere during vendor evaluation — replacing cold lists and one-off prospecting with omnipresence at the deciding moment.
Mandatory next steps, scheduled follow-ups, and education sequences keep the cycle moving between calls — built specifically to prevent the post-consult drop-off that kills typical pharma sales cycles.
We pre-qualify, document needs, and book directly on your calendar. Reminder sequences protect show rates and keep close velocity up.
Lists tell you who exists. The pixel tells you who's deciding.
OUTCOMES
In-market decision-makers — telehealth executives, hospital procurement, GPO contacts — not gatekeepers.
Precision decision-maker targeting means budget goes to buyers showing evaluation signals, not the whole industry — typically 20–40% lower acquisition costs than broad healthcare campaigns.
The same engine replicates from single-market to multi-market, state by state.
Buyer identification and engagement while intent is fresh — inside the window where the evaluation is still open.
Fewer conversations, with the right people, at the right moment.
YOUR SECTOR
HRT, GLP-1, peptides, dermatology, sterile lines. We identify providers actively seeking compounding partners, streamline outreach, and scale your prescriber network across states — precision targeting, compliance-first messaging.
Vendor evaluation cycles are long and fragile. We connect you with medical directors and operations leaders during their evaluation phase and hold engagement through the decision with a multi-touch approach.
GPO bids, hospital systems, international importers. We target procurement teams, position you for contract opportunities, and connect you with international buyers actively seeking US pharmaceutical suppliers.
Same engine, tuned to how your buyer actually buys.
ON THE RECORD
“Everything is DONE FOR YOU and their communication and follow up is incredible. It really shows that they care and are in this with you.”
— Dr. Blundy, Weight-Loss Clinic Owner
Their words, not ours — the videos are on /testimonials/.
THE PLAN
Fit analysis, market assessment, regulatory review. We qualify for fit: strategy sessions are reserved for established, high-revenue organizations.
SuperPixel installation, data ingestion, messaging framework, channel plan.
Targeted ads + strategic outreach + nurture sequences launch together; the booking system activates.
Sales collaboration, multi-market replication, continuous optimization.
You'll know what happens in week one, and what compounds after.
GUARDRAILS
Pricing is framed as cost-savings analysis and market comparison to stay inside the lines.
Aggressive on pipeline. Conservative on claims. In this industry, that's the only durable combination.
QUESTIONS
NEXT
One strategy session. We'll map your market, review your regulatory posture, and tell you whether the engine fits your growth stage.
Strategy sessions reserved for established, high-revenue organizations.